Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial

Abstract

This randomized clinical trial examines the superiority of a single dose of rituximab vs low-dose mycophenolate mofetil in preventing the recurrence of steroid-dependent nephrotic syndrome in children and young adults.

Trial registration: ClinicalTrials.gov NCT04402580.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ghiggeri reported grants from Italian Ministry of Health No Profit grant (Ricerca Finalizzata PE-2016-02361576) during the conduct of the study. No other disclosures were reported

Figures

Figure 1.. Schematic View of Trial Design

MMF indicates mycophenolate mofetil; PDN, prednisone.

Figure 2.. One-Year Relapse-Free Survival in the Rituximab and Mycophenolate Mofetil (MMF) Arms

The risk of relapse was 0.8 (12/15) in the MMF and 0.13 (2/15; P = .008 in the rituximab arm, with higher odds in the MMF arm (odds ratio, 26; 95% CI, 2.9-311.0).